Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (131-140 of 193) with videos related to

Pageof 20
Sort By:
ACR Open Rheumatology|May 15, 2024
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 TrialFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2023
Machine Learning Pipeline for Predicting Bone Marrow Edema Along the Sacroiliac Joints on Magnetic Resonance ImagingJoris Roels, Ann-Sophie De Craemer, Thomas Renson, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
Arthritis and Rheumatism|August 1, 2009
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximabJürgen Braun, Désirée van der Heijde, Mittie K Doyle, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 17, 2025
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation (GO-GUT), an Early Remission Induction StudyZuzanna Łukasik, Ann-Sophie De Craemer, Thomas Renson, et al.
Rheumatology (Oxford, England)|October 3, 2024
Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA studyHernán Maldonado-Ficco, Clementina López-Medina, Rodolfo Perez-Alamino, et al.
The Journal of Rheumatology|June 15, 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 StudiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2021
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label ExtensionAtul Deodhar, Désirée van der Heijde, Joachim Sieper, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Pageof 20

Showing results (131-140 of 193) with videos related to

Sort By:
Pageof 20
ACR Open Rheumatology|May 15, 2024
Upadacitinib in Active Non-radiographic Axial Spondyloarthritis: 1-Year Data From a Double-Blind, Randomized, Placebo-Controlled, Phase 3 TrialFilip Van den Bosch, Atul Deodhar, Denis Poddubnyy, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 6, 2023
Machine Learning Pipeline for Predicting Bone Marrow Edema Along the Sacroiliac Joints on Magnetic Resonance ImagingJoris Roels, Ann-Sophie De Craemer, Thomas Renson, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
Arthritis and Rheumatism|August 1, 2009
Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximabJürgen Braun, Désirée van der Heijde, Mittie K Doyle, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 17, 2025
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation (GO-GUT), an Early Remission Induction StudyZuzanna Łukasik, Ann-Sophie De Craemer, Thomas Renson, et al.
Rheumatology (Oxford, England)|October 3, 2024
Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA studyHernán Maldonado-Ficco, Clementina López-Medina, Rodolfo Perez-Alamino, et al.
The Journal of Rheumatology|June 15, 2026
Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results from Two Phase 3 StudiesXenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2021
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label ExtensionAtul Deodhar, Désirée van der Heijde, Joachim Sieper, et al.
Rheumatology and Therapy|March 18, 2024
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical TrialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trialAtul Deodhar, Filip Van den Bosch, Denis Poddubnyy, et al.
Pageof 20